Tribe Technologies
Trending >

Kneat has a 56 per cent upside, says Echelon

ksi stock

Software stock kneat.com (kneat.com Stock Quote, Charts, News, Analysts, Financials TSX:KSI) has been floating along for the past year without much ground gained, but investors will want to own a piece of this company, says Echelon Capital Markets analyst Rob Goff, who sees strong growth potential in Kneat. 

Goff delivered an update to clients on Monday where he reiterated a “Speculative Buy” rating and $4.20 target price, good for a projected return of 56 per cent at the time of publication.

Kneat is a Canadian software firm with operations in Limerick, Ireland, with a SaaS platform for business work processes such as equipment to computer validation and quality document management.

The company announced last week the signing of a three-year Master Services Agreement (MSA) with a division of one of the 20 largest pharmaceutical companies in the world by revenue. The contract is for e-logbook management for the company’s quality control labs, where the pharma company specializes in rare disease therapies.

The MSA is for sites in the US and the EU and has a go-live date pinned at sometime in the present quarter.

“Today’s win is not just a beachhead in another of the world’s largest pharmas; it also demonstrates the appeal of Kneat’s applicability for use cases outside of validation and the importance of our partners,” said Kneat CEO Eddie Ryan in a press release. “Whether it’s e-logbooks in a lab, or the commissioning and qualification of new equipment on a factory floor, Kneat is a key digital transformation partner for life science.”

Goff commented that Kneat now has 13 MSAs with top-20 global healthcare leaders, which shows the broad appeal of KSI’s platform, now the go-to standard with companies, according to Goff. The analyst pointed out recent contract wins such as another three-year MSA announced in January and a three-year contract signed this past October with one of the world’s largest healthcare companies.

“We continue to look for KSI to update its longstanding, narrowly defined land-and-expand target revenue potential of $50 million to reflect both its success developing broader service capabilities and initial inroads with adjacent markets including healthcare supply-chain providers and consumer cosmetics,” he wrote.

Goff left his estimates as-is for the moment, calling for KSI to hit 2023 revenue and adjusted EBITDA of $34.0 million and negative $4.9 million, respectively, and for 2024 revenue and EBITDA of $47.9 million and $0.7 million, respectively.

Goff said he’s bullish on Kneat’s organic growth as the company completes its transition to a SaaS model.

“We believe KSI represents an attractive investment valued at as 6.7x 2023 revenues and 10.6x EV/Gross Profits in the context of larger, slower growth peers Veeva Systems at 11.4x revenues and 15.6x EV/Gross Profits, and Aspen Technology at 11.7x revenues and 15.5x EV/Gross Profits,” Goff wrote.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

About The Author /

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.
insta twitter facebook

Comment